WuXi Biology HTS Platform 2.0 Launch

We are excited to announce the official launch of WuXi Biology HTS Platform 2.0, an advanced platform designed to enhance hit discovery and accelerate drug development. Here’s what’s new:

✅ Upgraded 370,000+ Diversity Small Molecule Library: A carefully curated collection with enhanced chemical diversity and drug-like properties to improve hit identification.

✅ Full Automation: Delivering precision, efficiency, and reproducibility at scale.

✅ Integrated Screening Platforms: Combining HTS, HCS, and ASMS platforms, providing diverse assay formats tailored to your research needs.

✅ Direct-to-Biology Platform: Integrating nanomole-scale high-throughput synthesis with direct biological assays to streamline and cost-effectively support hit triage and exploration.

Why Choose WuXi Biology HTS Platform?

With over 15 years of experience, our HTS platform has successfully supported hundreds of hit-finding campaigns across diverse targets, including GPCRs, enzymes, molecular glues, and more.

From assay development and miniaturization to fully automated screening, followed by hit triaging, cheminformatics, and hit-to-lead profiling, our integrated one-stop platform ensures the identification of high-quality chemical starting points, paving the way for robust lead candidates.

To learn more about our screening-related services, click HERE